|
1
|
DeSantis CE, Siegel RL, Sauer AG, Miller
KD, Fedewa SA, Alcaraz KI and Jemal A: Cancer statistics for
African Americans, 2016: Progress and opportunities in reducing
racial disparities. CA Cancer J Clin. 66:290–308. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirsch FR, Suda K, Wiens J and Bunn PA Jr:
New and emerging targeted treatments in advanced non-small-cell
lung cancer. Lancet. 388:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hähle A, Merz S, Meyners C and Hausch F:
The many faces of FKBP51. Biomolecules. 9:E352019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Staibano S, Mascolo M, Ilardi G, Siano M
and De Rosa G: Immunohistochemical analysis of FKBP51 in human
cancers. Curr Opin Pharmacol. 11:338–347. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Romano S, Di Pace A, Sorrentino A, Bisogni
R, Sivero L and Romano MF: FK506 binding proteins as targets in
anticancer therapy. Anticancer Agents Med Chem. 10:651–656. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stechschulte LA and Sanchez ER: FKBP51-a
selective modulator of glucocorticoid and androgen sensitivity.
Curr Opin Pharmacol. 11:332–337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cioffi DL, Hubler TR and Scammell JG:
Organization and function of the FKBP52 and FKBP51 genes. Curr Opin
Pharmacol. 11:308–313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang L: FKBP51 regulation of AKT/protein
kinase B phosphorylation. Curr Opin Pharmacol. 11:360–364. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jääskeläinen T, Makkonen H and Palvimo JJ:
Steroid up-regulation of FKBP51 and its role in hormone signaling.
Curr Opin Pharmacol. 11:326–331. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ni L, Yang CS, Gioeli D, Frierson H, Toft
DO and Paschal BM: FKBP51 promotes assembly of the Hsp90 chaperone
complex and regulates androgen receptor signaling in prostate
cancer cells. Mol Cell Biol. 30:1243–1253. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takaoka M, Ito S, Miki Y and Nakanishi A:
FKBP51 regulates cell motility and invasion via RhoA signaling.
Cancer Sci. 108:380–389. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hou J and Wang L: FKBP5 as a selection
biomarker for gemcitabine and Akt inhibitors in treatment of
pancreatic cancer. PLoS One. 7:e362522012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pei H, Li L, Fridley BL, Jenkins GD,
Kalari KR, Lingle W, Petersen G, Lou Z and Wang L: FKBP51 affects
cancer cell response to chemotherapy by negatively regulating Akt.
Cancer Cell. 16:259–266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dong J, Jiao Y, Mu W, Lu B, Wei M, Sun L,
Hu S, Cui B, Liu X, Chen Z and Zhao Y: FKBP51 decreases cell
proliferation and increases progestin sensitivity of human
endometrial adenocarcinomas by inhibiting Akt. Oncotarget.
8:80405–80415. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luo K, Li Y, Yin Y, Li L, Wu C, Chen Y,
Nowsheen S, Hu Q, Zhang L, Lou Z and Yuan J: USP49 negatively
regulates tumorigenesis and chemoresistance through FKBP51-AKT
signaling. EMBO J. 36:1434–1446. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fagerberg L, Hallström BM, Oksvold P,
Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S,
Danielsson A, Edlund K, et al: Analysis of the human
tissue-specific expression by genome-wide integration of
transcriptomics and antibody-based proteomics. Mol Cell Proteomics.
13:397–406. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li L, Lou Z and Wang L: The role of FKBP5
in cancer aetiology and chemoresistance. Br J Cancer. 104:19–23.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Romano S, D'Angelillo A, Pacelli R,
Staibano S, De Luna E, Bisogni R, Eskelinen EL, Mascolo M, Calì G,
Arra C and Romano MF: Role of FK506-binding protein 51 in the
control of apoptosis of irradiated melanoma cells. Cell Death
Differ. 17:145–157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gassen NC, Hartmann J, Schmidt MV and Rein
T: FKBP5/FKBP51 enhances autophagy to synergize with antidepressant
action. Autophagy. 11:578–580. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cancer Genome Atlas Research Network, .
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Donzelli S, Strano S and Blandino G: YAP
and p73: A Matter of mutual specificity in tumor suppression. The
Hippo Signaling Pathway Cancer. 147–172. 2013. View Article : Google Scholar
|
|
24
|
Makkonen H, Kauhanen M, Paakinaho V,
Jääskeläinen T and Palvimo JJ: Long-range activation of FKBP51
transcription by the androgen receptor via distal intronic
enhancers. Nucleic Acids Res. 37:4135–4148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim YY, Jee HJ, Um JH, Kim YM, Bae SS and
Yun J: Cooperation between p21 and Akt is required for
p53-dependent cellular senescence. Aging Cell. 16:1094–1103. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cordani M, Butera G, Pacchiana R and
Donadelli M: Molecular interplay between mutant p53 proteins and
autophagy in cancer cells. Biochim Biophys Acta Rev Cancer.
1867:19–28. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lieber M, Smith B, Szakal A, Nelson-Rees W
and Todaro G: A continuous tumor-cell line from a human lung
carcinoma with properties of type II alveolar epithelial cells. Int
J Cancer. 17:62–70. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jemal A, Murray T, Ward E, Samuels A,
Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer Statistics,
2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang L, Ma L, Xu F, Zhai W, Dong S, Yin L,
Liu J and Yu Z: Role of long non-coding RNA in drug resistance in
non-small cell lung cancer. Thorac Cancer. 9:761–768. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Balsevich G, Häusl AS, Meyer CW,
Karamihalev S, Feng X, Pöhlmann ML, Dournes C, Uribemarino A,
Santarelli S and Labermaier C: Stress-responsive FKBP51 regulates
AKT2-AS160 signaling and metabolic function. Nature Communications.
8((1)): 17252017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Velasco AM, Gillis KA, Li Y, Brown EL,
Sadler TM, Achilleos M, Greenberger LM, Frost P, Bai W and Zhang Y:
Identification and validation of novel androgen-regulated genes in
prostate cancer. Endocrinology. 145:3913–3924. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Romano S, D'Arrigo P, Tufano M, Staibano
S, Rea A, Merolla F, Ilardi G, Petrella A and Romano MF: TRAF2 and
FKBP51 as possible markers for identification of suitable melanoma
tumors for tumor necrosis factor-α inhibition. Melanoma Res.
29:145–150. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen J, Xie F, Zhang L and Jiang WG: iASPP
is over-expressed in human non-small cell lung cancer and regulates
the proliferation of lung cancer cells through a p53 associated
pathway. BMC Cancer. 10:6942010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fu X, Xu L, Qi L, Tian H, Yi D, Yu Y, Liu
S, Li S, Xu Y and Wang C: BMH-21 inhibits viability and induces
apoptosis by p53-dependent nucleolar stress responses in SKOV3
ovarian cancer cells. Oncol Rep. 38:859–865. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Walsh JG, Cullen SP, Sheridan C, Lüthi AU,
Gerner C and Martin SJ: Executioner caspase-3 and caspase-7 are
functionally distinct proteases. Proc Natl Acad Sci USA.
105:12815–12819. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chipuk JE, Moldoveanu T, Llambi F, Parsons
MJ and Green DR: The BCL-2 family reunion. Mol Cell. 37:299–310.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chee JL, Saidin S, Lane DP, Leong SM, Noll
JE, Neilsen PM, Phua YT, Gabra H and Lim TM: Wild-type and mutant
p53 mediate cisplatin resistance through interaction and inhibition
of active caspase-9. Cell Cycle. 12:278–288. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kato S, Han SY, Liu W, Otsuka K, Shibata
H, Kanamaru R and Ishioka C: Understanding the function-structure
and function-mutation relationships of p53 tumor suppressor protein
by high-resolution missense mutation analysis. Proc Natl Acad Sci
USA. 100:8424–8429. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Feng X, Liu H, Zhang Z, Gu Y, Qiu H and He
Z: Annexin A2 contributes to cisplatin resistance by activation of
JNK-p53 pathway in non-small cell lung cancer cells. J Exp Clin
Cancer Res. 36:1232017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sarin N, Engel F, Kalayda GV, Mannewitz M,
Cinatl J Jr, Rothweiler F, Michaelis M, Saafan H, Ritter CA, Jaehde
U and Frötschl R: Cisplatin resistance in non-small cell lung
cancer cells is associated with an abrogation of cisplatin-induced
G2/M cell cycle arrest. PLoS One. 12:e01810812017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang G, Reed E and Li QQ: Molecular basis
of cellular response to cisplatin chemotherapy in non-small cell
lung cancer (Review). Oncol Rep. 12:955–965. 2004.PubMed/NCBI
|
|
42
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology Group, : Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
